- Company
- Genome & Co acquires US firm to enter CDMO business
- by An, Kyung-Jin Sep 9, 2021 05:55am
- The KOSDAQ listed Genome & Company has acquired a manufacturing facility in the US to enter the microbiome contract development and manufacturing organization (CDMO) business. Through the acquire, the company aims to rise to a leader in both R&D and production in the microbiome market, a field with high growth potential. On the 8th, Genom
- Company
- Leclaza can be prescribed at general hospitals
- by An, Kyung-Jin Sep 9, 2021 05:54am
- Leclaza(Lazertinib Mesylate Monohydrate), a new domestic drug, is targeting the domestic lung cancer treatment market. As more than 30 major medical institutions nationwide were able to prescribe in about eight months of domestic permission, it has entered the domestic market competition, which forms 150 billion won a year. According to t
- Company
- Alunbrig proves the effectiveness of epilepsy patients
- by Sep 9, 2021 05:54am
- Competition is fierce for the first standard treatment as the second and third generation drugs, which are next-generation drugs, appear one after another in the ALK-positive non-small cell lung cancer treatment market. Target anticancer drugs targeting ALK mutations include the first generation Xalkori (Crizotinib), the second generation Zy
- Company
- It would have been a big trouble if no improvement
- by Chon, Seung-Hyun Sep 8, 2021 06:07am
- Pharmaceutical companies are actively working on transferring drug copyrights. As drug prices of transfer and transfer drugs are allowed, the transfer of permission rights due to mergers and acquisitions or corporate separation is speeding up. It is trying to enter the new generic market by receiving expensive products from other companies. A
- Company
- Tagrisso has established itself as an EGFR treatment
- by Sep 7, 2021 05:53am
- Lung cancer is the No. 1 cancer death rate among Koreans, but treatment is greatly evolving, with the 5-year survival rate more than tripling over 20 years. What had a significant impact on this was the EGFR target treatment. Targeted treatments targeting EGFR mutations have dramatically improved the overall survival period of patients. Am
- Company
- Downfall of Cialis·Viagra…market taken over by generics
- by Chon, Seung-Hyun Sep 6, 2021 05:59am
- ‘Viagra,’ which had once held a commanding lead over the erectile dysfunction treatment market, is having trouble making a comeback. After being taken over by domestic generics Palpal,’ and ‘Sendom,’ it had also been outrun by another local generic, ‘Gugu.’ Lilly’s Cialis is also having trouble making a comeback due to generic competitio
- Company
- Forxiga will become a basic treatment for chronic kidney dz
- by Sep 6, 2021 05:58am
- "SGLT-2 inhibitors are no longer diabetes drugs. It will be recognized by doctors of kidney medicine as a basic medicine that protects kidney function and is good for use with other medicines." Physicians expect SGLT-2 inhibitors, which have expanded their scope to kidney treatments. Choi Bum-soon, a professor of kidney medicine at the Universi
- Company
- Boryung released Avastin Biosimilar for the first time
- by An, Kyung-Jin Sep 5, 2021 08:24pm
- Boryung announced that it will sell its anti-cancer biosimilar "Onbevezy" introduced by Samsung Bioepis in the domestic market from the 1st. Onbevezy is a biosimilar product of the blockbuster anti-cancer drug Avastin (Bevacizumab) developed by Roche. Samsung Bioepis proved the equivalent effect and safety of its original product Avastin t
- Company
- Academia supports 1st-line reimbursement of Tagrisso
- by Eo, Yun-Ho Sep 3, 2021 06:03am
- The lung cancer societies are supporting the need to extend insurance benefits for ‘Tagrisso’ to 1st line treatment in lung cancer. In July, AstraZeneca Korea had reduced the standards and reapplied to extend reimbursement to the reduced scope for its 3rd generation EGFR TKI Tagrisso (osimertinib). However, the Health Insurance Review a
- Company
- Kymriah was virtually pending at the Committee
- by Eo, Yun-Ho Sep 2, 2021 05:59am
- It wasn't easy: the listing of the super expensive one-shot treatment 'Kymriah's insurance benefits was discussed but put on hold. According to related industries, Novartis Korea's world's first CAR-T treatment, Kymriah(Tisagenlecleucel), was virtually pending at the HIRA Cancer Drugs Benefit Appraisal Committee on the 1st. However, based on
